Three Acquisitions and Highest Quarterly Revenue to Date

Oslo, Norway, 26 February 2025: Today, Omda AS ("Omda"), the leading Nordic
provider of software for specialist healthcare and emergency medicine, published
its results for the fourth quarter of 2024.

Revenue for the quarter increased to NOK 116 million, marking Omda's highest
ever. Recurring revenue grew by 6% in the quarter to NOK 86 million. The
full-year revenue for 2024 of NOK 429 million and the adjusted EBITDA margin of
15% are both marginally above Omda's guidance published on 20 December. The
reported EBITDA margin of 5% for the quarter reflects one-off costs that ensure
significantly reduced expenses going into 2025.


Omda's CEO, Sverre Flatby, commented on the quarter:

"The completed restructuring has resulted in significantly lower run rate on the
cost side. This, combined with more than 30 consecutive quarters of increasing
recurring revenue, gives us confidence in our 2025 guidance."

With an organic business on track to reach the 30% EBITDA margin guiding and a
reassuring liquidity position, Flatby considers the fourth quarter of 2024 to
include key events with long-term value creation potential:

"The closing of Predicare, along with the announced acquisitions of Aweria and
Dermicus, introduces new AI functionality and medical decision support, opening
up further cross-selling opportunities," says Flatby. 

"As a niche provider, we are becoming increasingly specialised through selective
acquisitions that create added value for both customers and shareholders," he
concludes.

Highlights from the report:
o       Q4 2024 total revenue: 116 MNOK vs. 109 MNOK in Q4 2023
o	Recurring revenue grew 6% to 86 MNOK, accounting for 75% of total sales in the
quarter
o	Adjusted EBITDA (excl. one-offs) at 14%